¥È¥Ã¥×¥Ú¡¼¥¸¤Ø°Üư

¤³¤Î¥Ú¡¼¥¸¤ÎContents

 
  • ÀŲ¬¤¬¤ó¥»¥ó¥¿¡¼ÉÂÍý°åÍÜÀ®¹ÖºÂ};2019ǯÅÙÂè­·²óÌֱܹ餬ÎáÏÂ2ǯ1·î18Æü¡ÊÅÚ¡ËÀŲ¬»Ô¥µ¥ó¥Ñ¥ì¥¹¥Û¥Æ¥ë¤Ç³«ºÅ¤µ¤ì¤Þ¤·¤¿.--->»ÒµÜÆâËì¤ÎºÙ˦¿Ç¤ÈÉÂÍýÁÈ¿¥¿ÇÃÇ. ÉÂÍýÁÈ¿¥¤Ï¼¢²ì°å²ÊÂç³ØÉÂÍý¤ÎÎëëÀèÀ¸¤¬¤´¹Ö±é¤µ¤ì¤Þ¤·¤¿.
 
  • Âè84²óÃæÉô»ÙÉô¸ò¸«²ñ};¤¬ÎáϸµÇ¯12·î14Æü¡ÊÅÚ¡Ë̾¸Å²°»Ô̾¸Å²°Âç³Ø°å³ØÉôÃæ±û¿ÇÎÅÅïA3³¬¤Ç³«ºÅ¤µ¤ì¤Þ¤·¤¿.--->No84ÃæÉô¸ò¸«²ñ
 
  • IAP¥¹¥é¥¤¥É¥»¥ß¥Ê¡¼2019};¤¬ÎáϸµÇ¯11·î9Æü¡ÊÅÚ¡ËÅìµþÅÔÀéÂåÅĶèÆüËܶµ°é²ñ´Û¤Ç³«ºÅ¤µ¤ì¤Þ¤·¤¿.; ¿Õ¼ðáç¤ÈÈéÉæ¼ðáç¤Î¹Ö±é¤Ë½ÐÀʤ·¤Þ¤·¤¿.
 
  • ·ì±ÕÉÂÍý¥»¥ß¥Ê¡¼2019};¤¬ÎáϸµÇ¯9·î14Æü¡ÊÅÚ¡ËÅìµþÅÔ¹Á¶èÀÖºä1-8-1Àֺ䥤¥ó¥¿¡¼¥·¥Æ¥£¡¼Air4F¤Ç³«ºÅ¤µ¤ì¤Þ¤·¤¿.; MPN¤Î¹ü¿ñÁÈ¿¥¤òVS¤Ç¤ß¤Æ¿ÇÃǤ¹¤ë¥Ï¥ó¥º¥ª¥ó¥»¥ß¥Ê¡¼¤Ç¤¹.
 
  • Âè14²ó¹ü¿ñÉÂÍý¸¦µæ²ñ};¤¬ÎáϸµÇ¯9·î8Æü(Æü) ²¬»³¸©Àîºê°å²ÊÂç³Ø¹»¼ËÅï7³¬¥Þ¥ë¥Á¥á¥Ç¥£¥¢¶µ¼¼¤Ç³«ºÅ¤µ¤ì¤Þ¤·¤¿
    ÂæÉ÷15¹æ´ØÅìÀܶá¤Î¤¿¤á¡¢¿·´´Àþ¤¬¤Î¤­¤Ê¤ß±¿¹ÔÄä»ß¤Ë¤Ê¤ê, ÆÃÊֱ̹é¤È¶µ°é¹Ö±é¤Ï»²²Ã¤Ç¤­¤Þ¤·¤¿¤¬, ¾ÉÎã3Âê¤òݤ¯¤³¤È¤¬¤Ç¤­¤Þ¤»¤ó¤Ç¤·¤¿. ¤¢¤¢»Äǰ.
 
  • Âè17²óÅìµþ¹ü¿ñÉÂÍý¸¦µæ²ñ};¤¬ÎáϸµÇ¯£¸·î31Æü(ÅÚ) ÅìµþÅÔÃæ±û¶èȬ½Å½§ TKPÅìµþ±Ø¥«¥ó¥Õ¥¡¥ì¥ó¥¹¥»¥ó¥¿¡¼¤Ç³«ºÅ¤µ¤ì¤Þ¤·¤¿---> Âè17²óÅìµþ¹ü¿ñÉÂÍý¸¦µæ²ñ
 
  • B-cell Malignancy Academy_·ì±ÕÉÂÍý¸¡¶À²ñin´ØÅì2019 };¤¬ÎáϸµÇ¯£¸·î24Æü(ÅÚ) ÅìµþÅÔʸµþ¶è¸å³Ú¥Ù¥ë¥µ¡¼¥ëÈÓÅͶ¥Õ¥¡¡¼¥¹¥È¤Ç³«ºÅ¤µ¤ì¤Þ¤·¤¿--->¾ÉÎãȯɽ¤·¤Þ¤·¤¿. B-cell malignancy_Expert2019
 
  • Âè108²óÆüËÜÉÂÍý³Ø²ñÁí²ñ};¤¬ÎáϸµÇ¯5·î9Æü(ÌÚ)-11Æü(ÅÚ) ÅìµþÅÔÀéÂåÅĶè´Ý¤ÎÆâ Åìµþ¹ñºÝ¥Õ¥©¡¼¥é¥à¤Ç³«ºÅ¤µ¤ì¤Þ¤·¤¿--->Âè108²óÆüËÜÉÂÍý³Ø²ñÁí²ñ?
 
  • Âè15²óÅìµþ¹ü¿ñÉÂÍý¸¦µæ²ñ¤¬Ê¿À®31ǯ3·î16Æü(ÅÚ) ÅìµþÅÔÃæ±û¶èȬ½Å½§TKPÅìµþ±Ø¥«¥ó¥Õ¥¡¥ì¥ó¥¹¥»¥ó¥¿¡¼¤Ç³«ºÅ¤µ¤ì¤Þ¤·¤¿--->Âè15²óÅìµþ¹ü¿ñÉÂÍý¸¦µæ²ñ
     
  • Âè9²ó¥ê¥ó¥Õ¥©¥Þ¥Ë¥¢¤Ë¤Ê¤ë¤¿¤á¤Î¥ê¥ó¥Ñ¼ðÉÂÍý¿ÇÃÇ¥³¡¼¥¹¤¬Ê¿À®31ǯ3·î9Æü(ÅÚ) ÅìµþÅÔ¹Á¶è¹âÎØÅ쳤Âç³Ø¹âÎØ¥­¥ã¥ó¥Ñ¥¹1203¶µ¼¼¤Ç³«ºÅ¤µ¤ì¤Þ¤·¤¿¡£-->No9. ¥ê¥ó¥Õ¥©¥Þ¥Ë¥¢¤Î²ñ
 
  • Âè14²óÅìµþ¹ü¿ñÉÂÍý¸¦µæ²ñ¤¬10·î20Æü(ÅÚ) ÅìµþÅÔÀéÂåÅĶè¿ÀÅĽٲÏÂæ2-5-1¤ªÃã¤Î¿å¥Õ¥¡¡¼¥¹¥È¥Ó¥ë11F¥Î¥ô¥¡¥ë¥Æ¥£¥¹¥Õ¥¡¡¼¥ÞÅìµþ»ö̳½ê¤Ç³«ºÅ¤µ¤ì¤Þ¤·¤¿¡£
 
  • SPS¾ëÆîÉÂÍýº©Ã̲ñ2018¤¬10·î6Æü(ÅÚ) ÅìµþÅÔÉÊÀî¶è´ú¤ÎÂæ¾¼ÏÂÂç³ØÉ±¡Î×¾²¹ÖƲ¤Ç³«ºÅ¤µ¤ì¤Þ¤·¤¿¡£-->SPS¾ëÆîÉÂÍýº©Ã̲ñ2018
 
  • ·ì±ÕÉÂÍý¥»¥ß¥Ê- 2018¤¬9·î29Æü(ÅÚ) ÅìµþÅÔÀéÂåÅĶè¶åÃÊËÌ ¥Ù¥ë¥µ¡¼¥ë¶åÃÊ3F¥¤¥Ù¥ó¥È¥Û¡¼¥ë¤Ç³«ºÅ¤µ¤ì¤Þ¤·¤¿¡£MPN, MDS¤ÎÊÙ¶¯²ñ¤Ç¤¹.
 
  • Âè270²óSPSÀŲ¬ÉÂÍý°å²ñ¤¬8·î25Æü(ÅÚ) ÀŲ¬»ÔΩÀجɱ¡Åì´Û11F,C²ñµÄ¼¼¤Ç³«ºÅ¤µ¤ì¤Þ¤·¤¿¡£--->ÀŲ¬ÉÂÍý°å²ñNo270SPS¤Î¥Ú¡¼¥¸
 
  • Âè58²óÆüËÜÌÖÆâ·Ï³Ø²ñÁí²ñ¤¬6·î28Æü(ÌÚ)¤«¤é6·î30Æü(ÅÚ)¤Þ¤Ç °¦Ãθ©Ì¾¸Å²°»Ô¥¦¥¤¥ó¥¯¤¢¤¤¤Á, ¤Ç³«ºÅ¤µ¤ì¤Þ¤·¤¿¡£--->Âè58²ó ÆüËÜÌÖÆâ·Ï³Ø²ñÁí²ñ?¤Î¥Ú¡¼¥¸
 
  • Âè107²óÆüËÜÉÂÍý³Ø²ñÁí²ñ¤¬6·î21Æü(ÌÚ)¤«¤é6·î23Æü(ÅÚ)¤Þ¤Ç»¥ËÚ»ÔḚ̈ì¾òÀ¾£¹¡¡¥í¥¤¥È¥ó»¥ËÚ, ¥Ë¥È¥êʸ²½¥Û¡¼¥ë¤Ç³«ºÅ¤µ¤ì¤Þ¤·¤¿¡£--->Âè107²óÆüËÜÉÂÍý³Ø²ñÁí²ñ?¤Î¥Ú¡¼¥¸
 
  • Âè268²óSPSÀŲ¬ÉÂÍý°å²ñ¤¬4·î7Æü(ÅÚ) ÀŲ¬»ÔΩÀجɱ¡Åì´Û11F,C²ñµÄ¼¼¤Ç³«ºÅ¤µ¤ì¤Þ¤·¤¿¡£--->ÀŲ¬ÉÂÍý°å²ñNo268SPS¤Î¥Ú¡¼¥¸
 
  • Âè21²óÃæÉô»ÙÉô¥¹¥é¥¤¥É¥»¥ß¥Ê¡¼¤¬3·î24Æü(ÅÚ) ̾¸Å²°»Ô¿ðÊæ¶è¿ðÊæÄ®Ì¾¸Å²°»ÔΩÂç³Ø¤Ç³«ºÅ¤µ¤ì¤Þ¤·¤¿¡£--->Âè21²óÃæÉô¥¹¥é¥¤¥É¥»¥ß¥Ê¡¼¤Î¥Ú¡¼¥¸
 
  • Âè12²óÅìµþ¹ü¿ñÉÂÍý¸¦µæ²ñ¤¬3·î17Æü(ÅÚ) ÅìµþÅÔÀéÂåÅĶ褪Ãã¤Î¿å¥Õ¥¡¡¼¥¹¥È¥Ó¥ë11F ¥Î¥ô¥¡¥ë¥Æ¥£¥¹¥Õ¥¡¡¼¥ÞÅìµþ»ö̳½ê¤Ç³«ºÅ¤µ¤ì¤Þ¤·¤¿¡£--->Âè12²óÅìµþ¹ü¿ñÉÂÍý¸¦µæ²ñ¤Î¥Ú¡¼¥¸
 
  • Âè267²óÀŲ¬ÉÂÍý°å²ñSPS¤¬1·î27Æü ÀŲ¬»Ô, ÀŲ¬»ÔΩɱ¡À¾´Û11³¬²ñµÄ¼¼¤Ç³«ºÅ¤µ¤ì¤Þ¤·¤¿¡£
 
  • Âè80²óÃæÉô¸ò¸«²ñ¤¬12·î23Æü ̾¸Å²°»Ô, ̾¸Å²°Âç³Ø°å³ØÉôÉí°É±¡3³¬²ñµÄ¼¼¤Ç³«ºÅ¤µ¤ì¤Þ¤·¤¿¡£
     
  • 2017ǯÂè2²óÀŲ¬¤¬¤ó¥»¥ó¥¿¡¼ÉÂÍý°åÍÜÀ®¸¦½¤²ñ¤¬11·î25Æü ÀŲ¬»Ô, ¥µ¥ó¥Ñ¥ì¥¹¥Û¥Æ¥ë¤Ç³«ºÅ¤µ¤ì¤Þ¤·¤¿¡£¥Æ¡¼¥Þ¤Ï¥á¥é¥Î¡¼¥Þ, ¿À·ÐÉÂÍý¤Ç¤¹.
     
  • Ê¿À®29ǯ¾ëÆîÉÂÍý-SPS¹çƱº©Ã̲ñ(Âè266²óSPS)¤¬11·î11Æü, ÀŲ¬¸©»°Åç»Ô »°Åç»Ôʸ²½²ñ´Û¤Ç³«ºÅ¤µ¤ì¤Þ¤·¤¿¡£¡¡
     
  • Âè63²óÆüËÜÉÂÍý³Ø²ñ½©´üÆÃÊÌÁí²ñ¤¬11·î2Æü-3Æü, ÅìµþÅÔÀéÂåÅĶè°ì¥Ä¶¶ ÆüËܶµ°é²ñ´Û¤Ç³«ºÅ¤µ¤ì¤Þ¤·¤¿¡£¡¡ÉÂÍý¿ÇÃÇÆÃÊֱ̹é±éÂê¤Ï¡Ö¾®»ù¼ðáç¤ÎÉÂÍý¿ÇÃÇ¡×, ¡ÖǾ¼ðáç¤Î¿·WHOʬÎà¿ÇÃǡפǤ·¤¿.
     
  • ·ì±ÕÉÂÍý¥»¥ß¥Ê¡¼2017¤¬9·î30Æü, ÅìµþÅÔÀéÂåÅĶè¶åÃÊË̥٥륵¡¼¥ë¶åÃÊ3³¬¥Û¡¼¥ë¤Ç³«ºÅ¤µ¤ì¤Þ¤·¤¿¡£¥Æ¡¼¥Þ¤Ï¹ü¿ñÁý¿£À­¼ðáç¤Ç¤¹.
     
  • É;¾GaucherÉÂ¥»¥ß¥Ê¡¼¤¬9·î28Æü¡¡É;¾»Ô, ¥³¥ó¥³¥ë¥É¥Û¥Æ¥ë¤Ç³«ºÅ¤µ¤ì¤Þ¤·¤¿¡£¾ÉÎãÊó¹ð2Âê¤È, Royal Free London Hospital Dr.Uma Ramaswami¤ÎSpecial lecuture¤¬¤¢¤ê¤Þ¤·¤¿¡£
     
  • 2017ǯÂè1²óÀŲ¬¤¬¤ó¥»¥ó¥¿¡¼ÉÂÍý°åÍÜÀ®¸¦½¤²ñ¤¬9·î9Æü ÀŲ¬»Ô, ÃæÅç²°¥°¥é¥ó¥É¥Û¥Æ¥ë¤Ç³«ºÅ¤µ¤ì¤Þ¤·¤¿¡£¥Æ¡¼¥Þ¤ÏÆý´â, ¿Õ´â¤Ç¤¹.
     
  • Âè13²ó¹ü¿ñÉÂÍý¸¦µæ²ñ¤¬8·î27Æü, ÁÒÉß»ÔÀîºê°å²ÊÂç³Ø¹»¼ËÅï7F¥Þ¥ë¥Á¥á¥Ç¥£¥¢¶µ¼¼¤Ç³«ºÅ¤µ¤ì¤Þ¤·¤¿¡£¥Æ¡¼¥Þ¤Ï¡ÖÀÖ²êµå¡×¤Ç¤¹.
     
  • Âè265²óÀŲ¬ÉÂÍý°å²ñSPS8·î26Æü¡¡ÀŲ¬»Ô, ÀŲ¬»ÔΩÀجɱ¡Åì´Û11FC²ñµÄ¼¼¤Ç³«ºÅ¤µ¤ì¤Þ¤·¤¿¡£--->Âè265²óSPS?
     
  • Âè11²óÅìµþ¹ü¿ñÉÂÍý¸¦µæ²ñ¤¬ÅìµþÅÔÀéÂåÅĶè¿ÀÅĽٲÏÂæ2-5-1¥Î¥ô¥¡¥ë¥Æ¥£¥¹¥Õ¥¡¡¼¥ÞÅìµþ»ö̳½ê¤Ç³«ºÅ¤µ¤ì¤Þ¤·¤¿¡£--->Âè11²óÅìµþ¹ü¿ñÉÂÍý¸¦µæ²ñ
     
  • Âè79²óÃæÉô¸ò¸«²ñ¤¬7·î1Æü(ÅÚ)¤«¤é7·î2Æü(Æü)¤Þ¤ÇÉÙ»³»Ô¤Ç³«ºÅ¤µ¤ì¤Þ¤·¤¿.¡¡
     
  • Âè57²óÌÖÆâ·Ï³Ø²ñÁí²ñ¤¬6·î29Æü(ÌÚ)¤«¤é7·î1Æü(ÅÚ)¤Þ¤ÇÅìµþÅÔ¿·½É¶èµþ²¦¥×¥é¥¶¥Û¥Æ¥ë¤Ç³«ºÅ¤µ¤ì¤Þ¤·¤¿.¡¡T-cell lymphoma´ØÏ¢¤Î¹Ö±é¤¬Áý¤¨¤Þ¤·¤¿¤Í¡£
     
  • Âè264²óÀŲ¬ÉÂÍý°å²ñ(SPS)¤¬6·î24Æü(ÅÚ) ÀŲ¬»Ô, ÀŲ¬»ÔΩɱ¡À¾´Û11³¬²ñµÄ¼¼¤Ç³«ºÅ¤µ¤ì¤Þ¤·¤¿¡£-->ÀŲ¬ÉÂÍý°å²ñ
     
  • Âè10²óÅìµþ¹ü¿ñÉÂÍý¸¦µæ²ñÆÃÊÌ´ë²è-¹ü¿ñÁý¿£À­¼À´µ¤ÎÉÂÍýɸËܤ˴·¤ì¤è¤¦. 100¾ÉÎã¤ÎMPN¥¹¥é¥¤¥ÉɸËܤò¤ß¤ë²ñ¤¬2017ǯ6·î3Æü, 4Æü, ¿ÀÆàÀ°ËÀª¸¶»ÔÅ쳤Âç³Ø°ËÀª¸¶¹»¼ËÁÈ¿¥¼Â½¬¼¼¤Ç³«ºÅ¤µ¤ì¤Þ¤·¤¿¡£
     
  • Âè106²óÆüËÜÉÂÍý³Ø²ñÁí²ñ¤¬4·î27Æü¤«¤é29Æü(ÅÚ) ÅìµþÅÔ¿·½É¶èÀ¾¿·½É µþ²¦¥×¥é¥¶¥Û¥Æ¥ë¤Ç³«ºÅ¤µ¤ì¤Þ¤·¤¿¡£²ñ¾ì¤¬¤¹¤³¤·¶¹¤«¤Ã¤¿¤Ç¤¹¤Í¡£
     
  • ÆüËÜÉÂÍý³Ø²ñÃæÉô»ÙÉôÂè20²ó¥¹¥é¥¤¥É¥»¥ß¥Ê¡¾¤¬3·î25Æü(ÅÚ) °¦Ãθ©Ë­ÌÀ»Ô¡¡Æ£ÅÄÊÝ·ò±ÒÀ¸Âç³Ø¡¡À¸³¶¶µ°é¸¦½¤Åï2¹æ´Û4³¬¤Ç³«ºÅ¤µ¤ì¤Þ¤·¤¿.-->Âè20²óÃæÉô¥¹¥é¥¤¥É¥»¥ß¥Ê¡¼
     
  • Âè9²óÅìµþ¹ü¿ñÉÂÍý¸¦µæ²ñ¤¬3·î20Æü(·î½ËÆü),ÅìµþÅÔÀéÂåÅĶè¿ÀÅĽٲÏÂæ2-5-1¥Î¥ô¥¡¥ë¥Æ¥£¥¹¥Õ¥¡¡¼¥ÞÅìµþ»ö̳½ê¤Ç³«ºÅ¤µ¤ì¤Þ¤·¤¿¡£''--->Âè9²óÅìµþ¹ü¿ñÉÂÍý¸¦µæ²ñ
     
  • ÀŲ¬¤¬¤ó¥»¥ó¥¿¡¼ÉÂÍýÀìÌç°åÍÜÀ®¹ÖºÂ¤¬2·î10Æü(ÅÚ) ÀŲ¬¥°¥é¥ó¥É¥Û¥Æ¥ëÃæÅç²°¤Ç³«ºÅ¤µ¤ì¤Þ¤·¤¿.
     
  • Âè262²óÀŲ¬ÉÂÍý°å²ñ(SPS)¤¬1·î28Æü(ÅÚ) ÀŲ¬»Ô, ÀŲ¬»ÔΩɱ¡Åì´Û11³¬¹ÖƲ¤Ç³«ºÅ¤µ¤ì¤Þ¤·¤¿¡£-->ÀŲ¬ÉÂÍý°å²ñ
     
  • Âè78²óÆüËÜÉÂÍý³Ø²ñÃæÉô»ÙÉô¸ò¸«²ñ¤¬ 12·î17Æü(ÅÚ) ̾¸Å²°»Ô̾¸Å²°Âç³ØÉ±¡3³¬¹ÖƲ¤Ç³«ºÅ¤µ¤ì¤Þ¤·¤¿¡£-->Âè78²óÃæÉô»ÙÉô¸ò¸«²ñ
     
  • Âè7²ó¥ê¥ó¥Õ¥©¥Þ¥Ë¥¢¤Ë¤Ê¤ë¤¿¤á¤Î¥ê¥ó¥Ñ¼ðÉÂÍý¿ÇÃÇ¥³¡¼¥¹¤¬'' 10·î29Æü(ÅÚ) ÅìµþÅÔ¹Á¶è¹âÎØ2-3-23¡¡Å쳤Âç³Ø¹âÎØ¥­¥ã¥ó¥Ñ¥¹ 1¹æ´Û1201¶µ¼¼¤Ç³«ºÅ¤µ¤ì¤Þ¤·¤¿¡£-->Âè7²ó¥ê¥ó¥Õ¥©¥Þ¥Ë¥¢¤Ë¤Ê¤ë¤¿¤á¤Î¥ê¥ó¥Ñ¼ðÉÂÍý¿ÇÃÇ¥³¡¼¥¹
 
  • ÀŲ¬ÉÂÍý°å²ñ(SPS)-¾ëÆîÉÂÍý¹çƱº©Ã̲ñ¤¬ 10·î23Æü(Æü) ÅìµþÅÔ¹¾Åì¶èË­½§5-1-38 ¾¼ÏÂÂç³Ø¹¾ÅìË­½§É±¡£¹³¬¹ÖƲ¤Ç³«ºÅ¤µ¤ì¤Þ¤·¤¿¡£-->SPS-¾ëÆîÉÂÍý
 
  • Âè56²óÆüËÜÌÖÆâ·Ï³Ø²ñ¡¦Âè26²ó¼ù¾õºÙ˦³Ø²ñ¡¦Âè19²óÆüËܹü¿ñÉÂÍý¸¦µæ²ñ ¤¬9·î1Æü(ÌÚ)-9·î3Æü(ÅÚ),·§Ëܸ©·§ËܻԥۥƥëÆü¹Ò·§Ëܤdz«ºÅ¤µ¤ì¤Þ¤·¤¿¡£--->Âè56²óÆüËÜÌÖÆâ·Ï³Ø²ñ, Âè19²óÆüËܹü¿ñÉÂÍý¸¦µæ²ñ
     
  • Âè8²óÅìµþ¹ü¿ñÉÂÍý¸¦µæ²ñ¤¬8·î20Æü(ÅÚ),ÅìµþÅÔÀéÂåÅĶè¿ÀÅĽٲÏÂæ2-5-1¥Î¥ô¥¡¥ë¥Æ¥£¥¹¥Õ¥¡¡¼¥ÞÅìµþ»ö̳½ê¤Ç³«ºÅ¤µ¤ì¤Þ¤·¤¿¡£--->Âè8²óÅìµþ¹ü¿ñÉÂÍý¸¦µæ²ñ
     
  • Âè77²óÆüËÜÉÂÍý³Ø²ñÃæÉô»ÙÉô¸ò¸«²ñ¤¬7·î1, 2Æü(ÅÚ,Æü) ÄŻԻ°½ÅÂç³Ø°å³ØÉôÂèÆóÎ×¾²¹ÖµÁÅï¤Ç³«ºÅ¤µ¤ì¤Þ¤·¤¿¡£ -->Âè77²ó¸ò¸«²ñ
     
  • Âè258²óÀŲ¬ÉÂÍý°å²ñ(SPS)¤¬6·î25Æü(ÅÚ) ÀŲ¬»Ô, ÀŲ¬»ÔΩɱ¡Åì´Û11F C²ñµÄ¼¼¤Ç³«ºÅ¤µ¤ì¤Þ¤·¤¿¡£-->ÀŲ¬ÉÂÍý°å²ñ
     
 
  • Âè257²óÀŲ¬ÉÂÍý°å²ñ(SPS)¤¬4·î23Æü(ÅÚ) ÀŲ¬»Ô, ÀŲ¬¸©Ã˽÷¶¦Æ±»²²è¥»¥ó¥¿-¡Ö¤¢¤¶¤ì¤¢¡×¤Ç³«ºÅ¤µ¤ì¤Þ¤·¤¿¡£-->ÀŲ¬ÉÂÍý°å²ñ
     
  • Âè7²óÅìµþ¹ü¿ñÉÂÍý¸¦µæ²ñ¤¬3·î21Æü(·î;½Õʬ¤ÎÆü),ÅìµþÅÔÀéÂåÅĶè¿ÀÅĽٲÏÂæ2-5-1¥Î¥ô¥¡¥ë¥Æ¥£¥¹¥Õ¥¡¡¼¥ÞÅìµþ»ö̳½ê¤Ç³«ºÅ¤µ¤ì¤Þ¤·¤¿¡£--->Âè7²óÅìµþ¹ü¿ñÉÂÍý¸¦µæ²ñ
 
 
  • Âè256²óÀŲ¬ÉÂÍý°å²ñ(SPS)¤¬2·î13Æü(ÅÚ) ÀŲ¬»ÔΩÀجɱ¡12³¬¹ÖƲ¤Ç³«ºÅ¤µ¤ì¤Þ¤·¤¿¡£-->ÀŲ¬ÉÂÍý°å²ñ
     
  • Âè76²óÆüËÜÉÂÍý³Ø²ñÃæÉô»ÙÉô¸ò¸«²ñ¤¬12·î19Æü(ÅÚ), ̾¸Å²°»Ô, °¦Ãγر¡Âç³ØÆï¸µ¥­¥ã¥ó¥Ñ¥¹4¹æ´Û2F¤Ç³«ºÅ¤µ¤ì¤Þ¤·¤¿¡£--->Âè76²óÃæÉô¸ò¸«²ñ
     
  • Âè61²óÆüËÜÉÂÍý³Ø²ñ½©´üÆÃÊÌÁí²ñ¤¬11·î5-6Æü(ÌÚ-¶â)ÅìµþÅÔʸµþ¶èËܶ¿ ÅìµþÂç³Ø°ÂÅĹ֯²¤Ç³«ºÅ¤µ¤ì¤Þ¤·¤¿¡£
 
  • Âè254²óÀŲ¬ÉÂÍý°å²ñ(SPS)¡¤SPS-¾ëÆîÉÂÍý¹çƱ¥«¥ó¥Õ¥¡¥ì¥ó¥¹¤¬10·î24Æü(ÅÚ) »°Å羦¹©²ñµÄ½ê4²ñ¤ÇÀŲ¬¤¬¤ó¥»¥ó¥¿-À¤Ïÿͤˤè¤ê³«ºÅ¤µ¤ì¤Þ¤·¤¿¡£-->SPS-¾ëÆîÉÂÍý½¸Ã̲ñ¤Î¥Ú¡¼¥¸¤Ø
     
  • Âè253²óÀŲ¬ÉÂÍý°å²ñ(SPS)¤¬8·î30Æü(ÅÚ) ÀŲ¬»ÔΩÀجɱ¡12³¬¹ÖƲ¤Ç³«ºÅ¤µ¤ì¤Þ¤·¤¿¡£-->ÀŲ¬ÉÂÍý°å²ñ
     
  • Âè6²óÅìµþ¹ü¿ñÉÂÍý¸¦µæ²ñ¤¬8·î22Æü(ÅÚ),ÅìµþÅÔÀéÂåÅĶè¿ÀÅĽٲÏÂæ2-5-1¥Î¥ô¥¡¥ë¥Æ¥£¥¹¥Õ¥¡¡¼¥ÞÅìµþ»ö̳½ê¤Ç³«ºÅ¤µ¤ì¤Þ¤·¤¿¡£--->Âè6²óÅìµþ¹ü¿ñÉÂÍý¸¦µæ²ñ
     
  • Âè75²óÆüËÜÉÂÍý³Ø²ñÃæÉô»ÙÉô¸ò¸«²ñ¤¬7·î4Æü(ÅÚ), 5Æü ¿®½£Âç³Ø°å³ØÉôÉí°É±¡4³¬²ñµÄ¼¼¤Ç³«ºÅ¤µ¤ì¤Þ¤·¤¿¡£--->Âè75²óÃæÉô¸ò¸«²ñ
     
  • Âè252²óÀŲ¬ÉÂÍý°å²ñ(SPS)¤¬5·î30Æü(ÅÚ) ÀŲ¬»Ô¤¢¤¶¤ì¤¢4³¬²ñµÄ¼¼¤Ç³«ºÅ¤µ¤ì¤Þ¤·¤¿¡£-->ÀŲ¬ÉÂÍý°å²ñ
 

Âè104²óÆüËÜÉÂÍý³Ø²ñÁí²ñ¤¬4·î30Æü(ÌÚ)-5·î2Æü(ÅÚ) °¦Ãθ©Ì¾¸Å²°»Ô̾¸Å²°¹ñºÝ²ñµÄ¾ì¤Ç³«ºÅ¤µ¤ì¤Þ¤·¤¿. ¥ï¡¼¥¯¥·¥ç¥Ã¥×1 MDS¿ÇÃǤÎɸ½à²½¤òÌܻؤ·¤Æ,¤Ë¡ÖMDS¿ÇÃǤˤª¤±¤ëring sideroblasts¡×¤òȯɽ¤·¤Þ¤·¤¿¡£

 

Âè251²óÀŲ¬ÉÂÍý°å²ñ(SPS)¥«¥ó¥Õ¥¡¥ì¥ó¥¹¤¬3·î21Æü(ÅÚ) ÀŲ¬»ÔÃ˽÷¶¦Æ±»²²è¥»¥ó¥¿¡¼¤¢¤¶¤ì¤¢4F¤Ç³«ºÅ¤µ¤ì¤Þ¤·¤¿. -->ÀŲ¬ÉÂÍý°å²ñ

 
 

Âè18²óÃæÉô¥¹¥é¥¤¥É¥»¥ß¥Ê¡¼¤¬3·î14Æü(ÅÚ)¡¡°¦Ãθ©Ä¹µ×¼ê»Ô °¦Ãΰå²ÊÂç³Ø3³¬¹ÖƲ¤Ç³«ºÅ¤µ¤ì¤Þ¤·¤¿. -->ÃæÉô¥¹¥é¥¤¥É¥»¥ß¥Ê-

Âè250²óÀŲ¬ÉÂÍý°å²ñ(SPS)¤¬1·î24Æü(ÅÚ)¡¡ÀŲ¬»Ô ÀŲ¬»ÔΩÀجɱ¡À¾´Û12³¬¹ÖƲ¤Ç³«ºÅ¤µ¤ì¤Þ¤·¤¿. -->ÀŲ¬ÉÂÍý°å²ñ

Âè74²óÃæÉô»ÙÉô¸ò¸«²ñ¤¬12·î20Æü¡¡Ì¾¸Å²°»Ô ̾¸Å²°Âç³ØÉí°É±¡Ãæ±û¿ÇÎÅÅ³¬¹ÖƲ¤Ç³«ºÅ¤µ¤ì¤Þ¤·¤¿. -->No.74CHUBU

 

Âè249²óSPS-¾ëÆîÉÂÍý-ÀŲ¬ÉÂÍý°å²ñ¹çƱ¥«¥ó¥Õ¥¡¥ì¥ó¥¹¤¬11·î15Æü¡¡ÅìµþÅÔÈͶ¶è±ÉÄ®, ÅìµþÅÔ·ò¹¯Ä¹¼÷°åÎÅ¥»¥ó¥¿¡¼£³³¬Â裳²ñµÄ¼¼AB¤Ç³«ºÅ¤µ¤ì¤Þ¤·¤¿ -->SPS-¾ëÆîÉÂÍý

 

Âè3²óÆüËÜÌÖÆâ·Ï³Ø²ñ¥ê¥ó¥Ñ¼ð¥¹¥­¥ë¥¢¥Ã¥×¥»¥ß¥Ê¡¼¤¬11·î15Æü, 16Æü ̾¸Å²°»ÔÃæÂ¼¶è̾±ØAP̾¸Å²°8³¬²ñµÄ¼¼¤Ç³«ºÅ¤µ¤ì¤Þ¤·¤¿¡£--> ¥ê¥ó¥Ñ¼ð¥¹¥­¥ë¥¢¥Ã¥×¥»¥ß¥Ê¡¼

 

Â裵²ó¥ê¥ó¥Õ¥©¥Þ¥Ë¥¢¤Ë¤Ê¤ë¤¿¤á¤Î¥ê¥ó¥Ñ¼ðÉÂÍý¿ÇÃÇ¥³¡¼¥¹¤¬10·î18Æü, ²£ÉÍ»ÔÀ¾¶è¤ß¤Ê¤È¤ß¤é¤¤¤Ç³«ºÅ¤µ¤ì¤Þ¤·¤¿¡£-->Âè5²ó¥ê¥ó¥Õ¥©¥Þ¥Ë¥¢¤Ë¤Ê¤ë¤¿¤á¤Î¥ê¥ó¥Ñ¼ðÉÂÍý¿ÇÃÇ¥³¡¼¥¹

 

Âè248²óÀŲ¬ÉÂÍý°å²ñ(SPS)¤¬10·î18Æü, ÀŲ¬»Ô¤¢¤¶¤ì¤¢¤Ç³«ºÅ¤µ¤ì¤Þ¤·¤¿¡£-->Âè248²óÀŲ¬ÉÂÍý°å²ñ(SPS)

Âè73²óÆüËÜÉÂÍý³Ø²ñÃæÉô»ÙÉô¸ò¸«²ñ¤¬7·î5Æü, 6Æü¡¡´ôÉ츩¹â»³»Ô¹â»³ÀÖ½½»úɱ¡¤Ç³«ºÅ¤µ¤ì¤Þ¤·¤¿¡£-->Âè73²óÃæÉô»ÙÉô¸ò¸«²ñ

 

Âè54²óÆüËÜÌÖÆâ·Ï³Ø²ñÁí²ñ, Âè17²óÆüËÜ·ì±ÕÉÂÍý¸¦µæ²ñ¤¬6·î19-21Æü»³·Á¸©»³·Á»Ô»³·Á¹ñºÝ¥Û¥Æ¥ë¤Ç³«ºÅ¤µ¤ì¤Þ¤·¤¿¡£

 

Âè39²óÆüËܹü¿ñ¼ð³Ø²ñ³Ø½Ñ½¸²ñ¤¬5·î17Æü,18ÆüÀŲ¬¸©³ÝÀî»Ô³ÝÀ¥é¥ó¥É¥Û¥Æ¥ë¤Ç³«ºÅ¤µ¤ì¤Þ¤·¤¿¡£

 

Âè103²óÆüËÜÉÂÍý³Ø²ñÁí²ñ¤¬4·î24-26Æü¹­Åç»Ô¹ñºÝ²ñµÄ¾ì¤Ç³«ºÅ¤µ¤ì¤Þ¤·¤¿¡£

 

Âè5²óÅìµþ¹ü¿ñÉÂÍý¸¦µæ²ñ¤¬3·î21Æü¸æÃã¥Î¿åTKP¤ªÃã¤Î¿å²ñµÄ¼¼5³¬¤Ç³«ºÅ¤µ¤ì¤Þ¤·¤¿¡£--->Âè5²óÅìµþ¹ü¿ñÉÂÍý¸¦µæ²ñ¤Î¥Ú¡¼¥¸

 

Âè17²óÆüËÜÉÂÍý³Ø²ñÃæÉô»ÙÉô¥¹¥é¥¤¥É¥»¥ß¥Ê-¤¬3·î15Æü»°½ÅÂç³Ø¤Ç³«ºÅ¤µ¤ì¤Þ¤·¤¿

Âè72²óÆüËÜÉÂÍý³Ø²ñÃæÉô»ÙÉô¸ò¸«²ñ¤¬12·î21Æü̾¸Å²°»ÔΩÂç³ØÉí°É±¡¹ÖƲ¤Ç³«ºÅ¤µ¤ì¤Þ¤·¤¿¡£--->Âè72²óÃæÉô¸ò¸«²ñ

 

Âè59²óÆüËÜÉÂÍý³Ø²ñ½©´üÆÃÊÌÁí²ñ¤¬11·î21, 22Æü¹ÃÉܻԹÃÉÜÉٻβ°¥Û¥Æ¥ë¤Ç³«ºÅ¤µ¤ì¤Þ¤·¤¿¡£

 

ÆüËÜÌÖÆâ·Ï³Ø²ñ Âè2²ó¥ê¥ó¥Ñ¼ð¥¹¥­¥ë¥¢¥Ã¥×¥»¥ß¥Ê¡¼?¤¬11·î16, 17Æü̾¸Å²°»Ô¥¦¥¤¥ó¥¯¤¢¤¤¤Á¤Ç³«ºÅ¤µ¤ì¤Þ¤·¤¿¡£

 

Âè4²ó¥ê¥ó¥Õ¥©¥Þ¥Ë¥¢¤Ë¤Ê¤ë¤¿¤á¤Î¥ê¥ó¥Ñ¼ð¿ÇÃǸ¦µæ²ñ''¤¬11·î9ÆüÅìµþ¤Ç³«ºÅ¤µ¤ì¤Þ¤·¤¿¡£--->¹Ö±é, ¾ÉÎãÄó¼¨

 

Âè4²óÅìµþ¹ü¿ñÉÂÍý¸¦µæ²ñ¤¬10·î5ÆüÅìµþ¤Ç³«ºÅ¤µ¤ì¤Þ¤·¤¿¡£--->ÆÃÊֱ̹é, ¾ÉÎ㸡Ƥ3Îã¡£

Âè245²óÀŲ¬ÉÂÍý°å²ñSPS¤¬ÀŲ¬»Ô¤Ç³«ºÅ¤µ¤ì¤Þ¤·¤¿--->Âè245²óÀŲ¬ÉÂÍý°å²ñ

Âè71²óÃæÉô»ÙÉô¸ò¸«²ñ¤¬Ê¡°æ»Ô¤Ç³«ºÅ¤µ¤ì¤Þ¤·¤¿¡£--->Âè71²óÃæÉô»ÙÉô¸ò¸«²ñ¡¡À¤Ïÿ͡§Ê¡°æ¸©Î©É±¡Î×¾²ÉÂÍý²Ê¡¡³¤ºêÂÙ¼£ÀèÀ¸

 

Âè53²óÆüËÜÌÖÆâ·Ï³Ø²ñ, Âè16²óÆüËÜ·ì±ÕÉÂÍý¸¦µæ²ñ¤¬5·î16-18ÆüµþÅÔ, ¹ñΩµþÅÔ¹ñºÝ²ñ´Û¤Ç³«ºÅ¤µ¤ì¤Þ¤·¤¿¡£

 

Âè58²óÆüËÜÉÂÍý³Ø²ñ½©´üÆÃÊÌÁí²ñ 11·î22, 23Æü@̾¸Å²°»Ô¥¦¥¤¥ó¥¯¤¢¤¤¤Á

  • ÉÂÍý¿ÇÃÇ¥·¥ê¡¼¥º43¡¡¡¡Èó¼ðáçÀ­¥ê¥ó¥ÑÁý¿£¼À´µ¤ÎÉÂÍýÁÈ¿¥Áü¡¡à×¶¨°å²ÊÂç³ØÉÂÍý·ÁÂÖ¡¡¾®Åç ¾¡
  • ÉÂÍý¿ÇÃÇ¥·¥ê¡¼¥º44¡¡¡¡¹ü¼ðáçÉÂÍý¤Î¸«Êý¤È´ÕÊÌ¿ÇÃÇ¡¡¶âÂô°å²ÊÂç³Ø Î×¾²ÉÂÍý³Ø¡¡ÌîÅç ¹§Ç·
 

¹ñºÝÉÂÍý¥¢¥«¥Ç¥ß¡¼ÆüËÜ»ÙÉôIAP2012ǯ ¶µ°é¥·¥ó¥Ý¥¸¥¦¥à¡Ö°­À­¥ê¥ó¥Ñ¼ð¿ÇÃÇupdate2012¡×

  • 1. Äã°­À­ÅÙBºÙ˦¥ê¥ó¥Ñ¼ð¡¡¡¡Ë̳¤Æ»Âç³ØÉ±¡¡¡¾¾ÌîµÈ¹¨
  • 2. ¹â°­À­ÅÙBºÙ˦¥ê¥ó¥Ñ¼ð¡¡¡¡Å쳤Âç³Ø°å³ØÉô´ðÈ׿ÇÎųطÏÉÂÍý¿ÇÃdzء¡ÃæÂ¼Ä¾ºÈ
  • 3. T¤ª¤è¤ÓNKºÙ˦¥ê¥ó¥Ñ¼ð¡¡¡¡Ì¾¸Å²°Âç³ØÂç³Ø±¡°å³Ø·Ï¸¦µæ²Ê¡´ïÉÂÂÖ¿ÇÃdzء¡ÃæÂ¼±ÉÃË
  • 4. ¥Û¥¸¥­¥ó¥ê¥ó¥Ñ¼ð¡¡¡¡ºë¶Ì°å²ÊÂç³ØÁí¹ç°åÎÅ¥»¥ó¥¿¡ÝÉÂÍýÉô¡¡ÅĴݽ߰ì
  • 5. ¥ê¥ó¥Ñ¼ð¤Îʬ»ÒÉÂÂÖ¡¡¡¡Ì¾¸Å²°»ÔΩÂç³Ø°å³ØÉôÎ×¾²ÉÂÂÖÉÂÍý³Ø¡¡°ð³À ¹¨

¹ñºÝÉÂÍý¥¢¥«¥Ç¥ß¡¼ÆüËÜ»ÙÉôIAP2012ǯ¥¹¥é¥¤¥É¥»¥ß¥Ê¡Ý 11·î24Æü@̾¸Å²°Âç³Ø

¥¹¥é¥¤¥É¥»¥ß¥Ê

  • ÆýÁ£¿ËÀ¸¸¡¤ÎÉÂÍý¿ÇÃÇ¡¡ Àîºê°å²ÊÂç³ØÉÂÍý³Ø2 ¿¹Ã« ÂîÌé

Âè°ì²óÅìµþ¹ü¿ñÉÂÍý¸¦µæ²ñ

¾ÉÎ㸡Ƥ¤ÈÆÃÊֱ̹é

  • ¹ü¿ñÁý¿£À­¼ðáç¡Êmyeloproliferative neoplasms¡¨MPN¡Ë¤ÎÉÂÂÖ¡¢¿ÇÃǤȼ£ÎŤθ½ºß
    Åìµþ°å²ÊÂç³Ø¡¡·ì±ÕÆâ²Ê¡¡¸åÆ£¡¡ÌÀɧÀèÀ¸
  • ¹ü¿ñ¤òÁÈ¿¥¤Ç¸«¤ë¤È¤¤¤¦¤³¤È¡§Çò·ìɤλþ¶õ´ÖÉÂÍý
    ̾¸Å²°Âè°ìÀÖ½½»úɱ¡¡¡ÉÂÍýÉô¡¡°ËÆ£¡¡²íʸÀèÀ¸
     

ÀŲ¬¸©Î©ÀŲ¬¤¬¤ó¥»¥ó¥¿¡¼ÀìÌçÉÂÍý°åÍÜÀ®¸¦½¤²ñ

  • ÂçIJ¾åÈéÀ­¼ðáç¤ÎÉÂÍý¿ÇÃÇ?

Âè8²óÉÍ̾¸Ð¹ñºÝ¥»¥ß¥Ê- °­À­¥ê¥ó¥Ñ¼ð¤ÎÉÂÍý

Steven H. Swerdlow, Elias Campo, Masaru Kojima and Shigeo Nakamura
October 30-31, 2010, Hamamatsu Japan

Overview of 2008 WHO classification of malignant lymphoma

Steven H. Swerdlow

Current approach to the aggressive B-cell lymphpmas

Steven H. Swerdlow

Suppurative granulomatous lymphadenitis, atypical lymphoplasmacytic and immunoblastic proliferation(autoimmune disease-associated lymphadenopathy) and inflammatory pseudotumor of the lymph node

Masaru Kojima, Dokkyoh Uni.

Multicentric Castleman's disease and IgG4-related lymphoadenopathy

Masaru Kojima

Mantle cell lymphoma, Marginal zone lymphoma, and MALT Lymphoma

Elias Campo, Hospital Clinic, Uni. of Barcelona

Follicular lymphoma and its variant

Elias Campo

Angioimmunoblastic T-cell lymphoma

Shigeo Nakamura, Nagoya Uni. Hospital

Age-related EBV-associated B cell-LPD and Classical Hodgkin lymphoma

Shigeo Nakamura

 

Âè13²ó·ì±ÕÉÂÍý¸¦µæ²ñ¡¦Âè50²ó¥ê¥ó¥ÑÌÖÆâ·Ï³Ø²ñÁí²ñ 2010 (¿·³ã»Ô ¼ëºí¥á¥Ã¥»)

¥·¥ó¥Ý¥¸¥¦¥à2 WHO¥ê¥ó¥Ñ¼ðʬÎàÂè4ÈǤÎǧÃÎ, Íý²ò, ÊäŶ

ºÂĹ¡§ÅÄ´Ý ½ß°ì, ÃÝÆâ ¸­¸ã

¿ȯ¹ü¿ñ¼ð¼£ÎŤξ­ÍèŸ˾¤ÈÆüËܤˤª¤±¤ë¸½»þÅÀ¤Î¥Ù¥¹¥È¥×¥é¥¯¥Æ¥£¥¹

ÎëÌÚ ·û»Ë

ÆüËÜ¥ê¥ó¥ÑÌÖÆâ·Ï³Ø²ñ50ǯ¤Î¤¢¤æ¤ß

¼ÆÅÄ ¾¼

¥·¥ó¥Ý¥¸¥¦¥à3 BºÙ˦À­ËýÀ­¥ê¥ó¥ÑÀ­Çò·ìɤδðÁäÈÎ×¾²

ºÂĹ¡§ÎëµÜ½ß»Ê, ÀÄÌÚÄêÉ×

²áµî50ǯ¤Î¥ê¥ó¥Ñ¼ð¸¦µæ¤«¤é¤Î¶µ·± - ·ì´ÉÌȱֲêµåÀ­TºÙ˦¥ê¥ó¥Ñ¼ð¤Î¸¦µæ¤ò¿¶¤êÊ֤äÆ-

²¼»³ ÀµÆÁ

¥ê¥ó¥Ñ¼ð¸¦µæ¤Î¸½¾õ¤È̤Íè¤Ø¤ÎŸ˾

À¥¸Í ²ÃÂç

lymphomania¤Ë¤Ê¤ë¤¿¤á¤Î¥ê¥ó¥Ñ¼ðÉÂÍý¿ÇÃÇ¥³¡¼¥¹¡¡Â裱²óßÉ˦À­¥ê¥ó¥Ñ¼ð¤È¤½¤Î¼þÊÕ

»Ê²ñ¡§Ä¹Ã«Àî ¹ä

  • 1. ßÉ˦À­¥ê¥ó¥Ñ¼ð¥¢¥¦¥È¥é¥¤¥ó¡¡¡¡ÃÝÆâ¡¡¸­¸ã
  • 2. HE¥¹¥é¥¤¥É¤òÍѤ¤¤¿¾ÉÎãÄ輨¡¡ÃæÂ¼¡¡Ä¾ºÈ, ¾®Åç¡¡¾¡
  • 3. ßÉ˦À­¥ê¥ó¥Ñ¼ð¤Î¼£ÎÅ °ËƦÄÅ¡¡¹¨Æó
     

IAP¥¹¥é¥¤¥É¥»¥ß¥Ê¡¼2009 ¡ÊÅìµþÂ塹ÌÚ¡Ë

ÂñÕÁ£¼ðáç¤ÎÉÂÍý

Åìµþ°å²ÊÂç³Ø¡¡Ä¹Èø½Ó¹§

  • 092-1 Basal cell adenoma with a prominet adenoid cystic pattern
  • 092-2 Sialadenoma papilliferum
  • 092-3 Acinic cell carcinoma
  • 092-4 Intermediate-grade mucoepidermoid carcinoma, oncocytic variant
  • 092-5 Polymorphous low-grade adenocarcinoma
  • 092-6 Clear cell carcinoma, NOS
  • 092-7 Basal cell adenocarcinoma
  • 092-8 Epithelial-myoepithelial carcinoma
  • 092-9 Papillary cystadenocarcinoma
  • 092-10 Salivary duct carcinoma, invasive micropapillary variant, ex pleomorphic adenoma
  • 092-11 Myoepithelial carcinoma
  • 092-12 Carcinoma ex pleomorphic adenoma, non-invasive type

»ÒµÜÆâËì¾É¤È¤½¤Î´ØÏ¢¼ðáç

»³·ÁÂç³Ø°å³ØÉô¡¡ËÜ»³Äð°ì

ÉÂÍý³Ø²ñ¡´ï¿ÇÃÇ¥»¥ß¥Ê¡¼ 2009ÉÂÍý³Ø²ñ½©´üÁí²ñ

2009ǯ11·î20ÆüÅìµþÅÔÀéÂåÅĶè¶åÃʲñ´Û

ç¹Ç¹Ë¦À­¼ðáç

¹Ã¾õÁ£ßÉ˦¼ðáç

IAP¶µ°é¥·¥ó¥Ý¥¸¥¦¥à2008

»ÒµÜðôÉô¤ÎºÙ˦¿ÇNew Wave- Bethesda system¤ÈLiquid based cytology

IAP¥¹¥é¥¤¥É¥»¥ß¥Ê¡¼2008

¹ü¿ñ¤ÎÉÂÍý

µ×Î±ÊÆÂç³Ø¡¡ÂçÅç¹§°ì

Ç٤γ°²ÊÉÂÍýup date

ÃæÃ«¡¡¹Ôͺ¡¡¾¾¸¶½¤

ÉÂÍý³Ø²ñ¡´ï¿ÇÃÇ¥»¥ß¥Ê¡¼ 2008ÉÂÍý³Ø²ñ½©´üÁí²ñ

2008(@ Matsuyama)

2008ǯ11·î22Æü¾¾»³»ÔÁí¹ç¥³¥ß¥å¥Ë¥Æ¥£¡¼¥»¥ó¥¿¡¼

ÈéÉæÉÕ°´ï¼ðáç¤ÎÉÂÍý

¾®·¿¡ÁÃæ·¿¤Î¼ðáçºÙ˦¤«¤é¤Ê¤ëBºÙ˦¥ê¥ó¥Ñ¼ð¤ÎÉÂÍý¿ÇÃǤȤ½¤Î´ÕÊÌ-¥Þ¥ó¥È¥ëºÙ˦¥ê¥ó¥Ñ¼ð¤òÃæ¿´¤Ë

Âè7²ó°ß´â¤Î¥ê¥¹¥¯¥Õ¥¡¥¯¥¿¡¼¸¦µæ²ñ

Åìµþ³Ø½ÑÁí¹ç¥»¥ó¥¿¡¡2007ǯ6·î16Æü

¶µ°é¹Ö±é

£±¡¥°ß´â¤Ë¤ª¤±¤ë¥×¥í¥¹¥¿¥°¥é¥ó¥¸¥ó¹çÀ®¹ÚÁǤÎÌò³ä ¡¡¡¡Ã¤¸ý¡¡ÆÆ»Ö¡¡ÆüËܰå²ÊÂç³Ø¾Ã²½´ïÆâ²Ê

£²¡¥Ä²¾åÈé²½À¸¤«¤é¤Îʬ²½·¿°ß´â¤ÎȯÀ¸ ¡¡¡¡ÉðÆ£¡¡¹°¹Ô¡¡¼«¼£°å²ÊÂç³Ø¾Ã²½´ïÆâ²Ê

£³¡¥°ß¤¬¤óȯÀ¸¤Ë¤ª¤±¤ëWnt/¦Â-catenin¥·¥°¥Ê¥ë¤È¥×¥í¥¹¥¿¥°¥é¥ó¥¸¥óE2·ÐÏ© ¡¡¡¡ÂçÅç¡¡Àµ¿­¡¡¶âÂôÂç³Ø¤¬¤ó¸¦µæ½ê¼ðáç°äÅÁ³Ø¸¦µæÊ¬Ìî

GIST¤Î¿ÇÃǤȼ£ÎÅ--ÆüËÜÉÂÍý³Ø²ñÂè96²óÁí²ñ

GIST¤Î¿ÇÃǤȼ£ÎÅ

Dr. JKC Chan¤Î¹Ö±é¡¡

2006ǯ6·î ÆüËÜ·ì±ÕÉÂÍý¸¦µæ²ñ¹Ö±é¡§AN UPDATE ON IMMUNOHISTOCHEMISTRY IN HEMATOPATHOLOGY
¹Ö±éÆâÍÆ¤ò¸«¤ë

ÉÂÍý³Ø²ñ¡´ï¿ÇÃÇ¥»¥ß¥Ê¡¼

2007(@ Funabori,Edogawa-ku,Tokyo)

Ǿ¼ðáç¤ÎÉÂÍý

¶»Á£¼ðáç¤ÎÉÂÍý

IAP¶µ°é¥·¥ó¥Ý¥¸¥¦¥à

2007(@Tokyo-Yoyogi) ±ê¾ÉÀ­ÈéÉæ¼À´µ¡§Î×¾²°å¤¬µá¤á¤ëÉÂÍý¿ÇÃÇÊó¹ð½ñ

IAP¥¹¥é¥¤¥É¥»¥ß¥Ê

2007(@Tokyo-Yoyogi)

ÈéÉæÉÕ°´ï¼ðáç

ºë¶Ì°å²ÊÂç³ØÉÂÍý³Ø¶µ¼¼¡¡À¶¿å¡¡Æ»À¸

  • ¾ÉÎã062-1 Trichoepithelioma
  • ¾ÉÎã062-2 Malignant proliferating trichilemmal tumor
  • ¾ÉÎã062-3 Sebaceoma
  • ¾ÉÎã062-4 Syringocystadenoma papilliferum
  • ¾ÉÎã062-5 Apocrine hydradenoma
  • ¾ÉÎã062-6 Apocrine adenocarcinoma
  • ¾ÉÎã062-7 Eccrine spiradenoma
  • ¾ÉÎã062-8 Eccrine poroma
  • ¾ÉÎã062-9 Syringoma
  • ¾ÉÎã062-10 Porocarcinoma(in association with benign poroma)

¹Ã¾õÁ£¼ðáç-¿·WHOʬÎà

2006(@Wakayama)

ÆðÉô¼ðáç

»º¶È°å²ÊÂç³ØÉÂÍý³ØÂè°ì¹ÖºÂ¡¡¶¶ËÜ¡¡ÍÎ

  • ¾ÉÎã061-1¡¡Â¿·¿·¿»éËÃÆù¼ð pleomorphic liposarcoma
  • ¾ÉÎã061-2¡¡¸ÌºßÀ­Àþ°ÝÀ­¼ðáç solitary fibrous tumor
  • ¾ÉÎã061-3¡¡±ê¾ÉÀ­¶ÚÀþ°Ý²êºÙ˦¼ðáç inflammatory myofibroblastic tumor
  • ¾ÉÎã061-4¡¡Äã°­À­Àþ°ÝÇ´±ÕÀ­Æù¼ð low grade fibromyxoid sarcoma(Evans¼ðáç),giant collagen rosette·ÁÀ®°¡·¿
  • ¾ÉÎã061-5¡¡¶Ú·ì´É¼þÈé¼ð myopericyotoma, ·ì´ÉÊ¿³ê¶Ú¼ðÍÍÉôʬ¤òȼ¤¦ with angioleiomyoma-like area
  • ¾ÉÎã061-6¡¡¹Å²½À­¿À·Ð¼þËì¼ð sclerosing perineuroma
  • ¾ÉÎã061-7¡¡EwingÆù¼ð/¸¶»Ï¿À·Ð³°æõÍÕÀ­¼ðáç¥Õ¥¡¥ß¥ê¡¼ Ewing sarcoma/PNET family
  • ¾ÉÎã061-8¡¡Ã±Áê·¿Àþ°ÝÀ­³êËìÆù¼ð monomorphic fibrous synovial sarcoma
  • ¾ÉÎã061-9¡¡¶á°Ì·¿Îà¾åÈéÆù¼ð¡¡proximal-type epithelioid sarcoma
  • ¾ÉÎã061-10¡¡¹ü³°À­Ç´±Õ·¿Æð¹üÆù¼ð extraskeletal myxoid chondrosarcoma
  • ¾ÉÎã061-11¡¡°­À­·ì´É¼þ°ÏÎà¾åÈéºÙ˦¼ðáç malignant perivascular epithelioid cell neoplasm (malignant PEComa)

¾åÉô¾Ã²½´ÉÉÂÊÑ

Ê¡²¬Âç³Ø°å³ØÉôÉÂÍý³Ø¹ÖºÂ¡¡Æó¼¡¡Áï

  • ¾ÉÎã053-01 ¿©Æ»¡¦Ù¨Ê¿¾åÈé´â squamous cell carcinoma in situ
  • ¾ÉÎã053-02 ¿©Æ»¡¦Ù¨Ê¿¾åÈé´â squamous cell carcinoma in situ
  • ¾ÉÎã053-03 ¿©Æ»¡§Îà´ðÄìºÙ˦´â
  • ¾ÉÎã053-04 ¿©Æ»¡§¥Ð¥ì¥Ã¥È¿©Æ»
  • ¾ÉÎã053-05 °ß¡§¥ê¥ó¥Ñµå¿»½á¤òȼ¤¦´â Gastric carcinoma with lymphoid stroma
  • ¾ÉÎã053-06 °ß¡§ÆýƬ¾õÁ£´â
  • ¾ÉÎã053-07 °ß¡§ÆâʬÈçºÙ˦´â
  • ¾ÉÎã053-08 °ß¡§AFP»ºÀ¸À­°ß´â(AFP-producing gastric carcinoma)
  • ¾ÉÎã053-09 °ß¡§¼«¸ÊÌȱÖÀ­(A·¿)°ß±ê¤Ë¿ïȼ¤·¤¿Â¿È¯À­¥«¥ë¥Á¥Î¥¤¥É¼ðáç
  • ¾ÉÎã053-10 ½½Æó»ØÄ²¡§ßÉ˦À­¥ê¥ó¥Ñ¼ð
  • ¾ÉÎã053-11 ¾®Ä²¡§Ä²¾É·¿TºÙ˦À­¥ê¥ó¥Ñ¼ð
  • ¾ÉÎã053-12 ¶õIJ¡§¤Ó¤Þ¤óÀ­ÂçºÙ˦·¿BºÙ˦À­¥ê¥ó¥Ñ¼ð
  • ¾ÉÎã053-13 ²óIJ½ªËöÉô¡§¥Ð¡¼¥­¥Ã¥È¥ê¥ó¥Ñ¼ð

2005(@Tokyo)

»ÒµÜ¤ÎÁ£·ÏÉÂÊÑ-¿ÇÃǤÎpitfall

Åìµþ»ü·Ã²ñ°å²ÊÂç³Ø¡¡À¶Àîµ®»Ò

  • ¾ÉÎã042-1 Tubal metaplasia
  • ¾ÉÎã042-2 well differentiated mucionus adenocarcinoma, endocervical type
  • ¾ÉÎã042-3 lobular endocervical gland hyperplasia with atypia
  • ¾ÉÎã042-4 adenomyoma, endocervical type
  • ¾ÉÎã042-5 mesonephric remunant (mesonephric hyperplasia)
  • ¾ÉÎã042-6 atypical endometrial hyperplasia, complex
  • ¾ÉÎã042-7 disordered proliferative phase endometrium
  • ¾ÉÎã042-8 Endometrial polyp
  • ¾ÉÎã042-9 endometrial glandular and stromal breakdown
  • ¾ÉÎã042-10 a. Mullerian adenosarcoma
  • ¾ÉÎã042-10 b. Mullerian adenocarcoma with sarcomatous overgrowth
  • ¾ÉÎã042-11 atypical polypoid adenomyoma

¥ê¥ó¥ÑÀá¤ÎÈó¼ðáçÀ­ÉÂÊÑ

·²Çϸ©Î©¤¬¤ó¥»¥ó¥¿-¡¡¾®Å羡

2004(@Nagoya)

´Î¡¤Î¾®·ëÀáÉÂÊÑ

¶âÂôÂç³ØÂç³Ø±¡°å³Ø·Ï¸¦µæ²Ê·ÁÂÖµ¡Ç½ÉÂÍý³Ø¡¡Ãæ¾Â¡¡°ÂÆó

  • ¾ÉÎã041-1 ´Î¡¡§Atypical adenomatous hyperplasia of the liver( dysplastic nodule, high grade)
  • ¾ÉÎã041-2 ´Î¡¡§Well differentiated hepatocellular carcinoma arising in dysplastic nodule
  • ¾ÉÎã041-3 ´Î¡¡§Hepatocellular carcinoma with clear cell change, scirrhous type
  • ¾ÉÎã041-4 ´Î¡¡§Multiacinar hyperplastic nodule arising in idiopathic portal hypertention (IPH)
  • ¾ÉÎã041-5 ´Î¡¡§FNH-like hyperplastic nodule in alcholic fibrosis
  • ¾ÉÎã041-6 ´Î¡¡§Liver cell adenoma arising in pill-treated patient
  • ¾ÉÎã041-7 ´Î¡¡§Angiomyolipoma (AML) of the liver
  • ¾ÉÎã041-8 ´Î¡¡§Billiary microhamartoma (bile duct hamartoma, von Meyenburg complex)
  • ¾ÉÎã041-9 ´Î¡¡§bile duct adenoma

Ǿ¼Â¼Á¼ðáç

·²ÇÏÂç³Ø°å³ØÉôÂè°ìÉÂÍý³Ø¹ÖºÂ¡¡ÃæÎ¤¡¡Íΰì

  • ¾ÉÎã021-01 º¸Â¦Ç¾¼¼¡§Central neurocytoma WHO grade II
  • ¾ÉÎã021-02 ±¦¾®Ç¾È¾µå¡§Pilocytic astrocytoma, WHO grade I
  • ¾ÉÎã021-03 ±¦Á°¡¦Â¦Æ¬ÍÕ¡§Diffuse astrocytoma (fibrillary astrocytoma), WHO grade II
  • ¾ÉÎã021-04
  • ¾ÉÎã021-05
  • ¾ÉÎã021-06
  • ¾ÉÎã021-07
  • ¾ÉÎã021-08
  • ¾ÉÎã021-09
  • ¾ÉÎã021-10
  • ¾ÉÎã021-11
  • ¾ÉÎã021-12
  • ¾ÉÎã021-13
  • ¾ÉÎã021-14

ÉÍ̾¸Ð¹ñºÝ¥»¥ß¥Ê¡¼

2004ǯ¡¡Pathology of soft tissue tumor and slide seminar

 

JPIP-case °ìÍ÷

¢£ 2016ǯ-A

  • case01: °ßÇ´±Õ´â¡¡°ß, 92ºÐ½÷À­
  • case02: º®¹çÀ­æõºÙ˦¼ðáç ÀºÁã, 35ºÐÃËÀ­
  • case03: øÌÀºÙ˦·¿´ÎºÙ˦´â ´Î, 67ºÐ½÷À­
  • case04: ·ì´É¶Ú»éËüð angiomyolipoma ¿Õ¡, 37ºÐ½÷À­
  • case05: ¹ü³°EwingÆù¼ð¡¡ÂçÂÜ, 71ºÐÃËÀ­
  • case06: ÌÀºÙ˦Æù¼ð¡¡º¸²¼»è, 29ºÐ½÷À­
  • case07: ¿·Á·¿»éËÃÆù¼ð º¸¾å»è¿¼ÉôÆðÉôÁÈ¿¥, 72ºÐ½÷À­
  • case08: È¿±þÀ­ßÉ˦À­²á·ÁÀ®¡¡ÁÍ·Â¥ê¥ó¥ÑÀá 13ºÐÃË»ù
  • case09: Íñ²«Ç¹¼ðáç Yolksac tumor ±¦ÍñÁã, 19ºÐ½÷À­
  • case10: ÇżïÀ­Ê¢ËìÊ¿³ê¶Ú¼ð¾É¡¡ÍñÁã¤ÈÊ¢Ëì, 44ºÐ½÷À­

¢£ 2015ǯ-A

  • case01: ÂñÕÁ£Æ³´É´â¡¡¼ª²¼Á£, 79ºÐ½÷À­
     
  • case02: ¿À·ÐÀá¿À·Ð²ê¼ð¡¡ËµÀÔÄÇ, 4ºÐ½÷»ù
     
  • case03: °­À­·ì´É¼þ°ÏÎà¾åÈéºÙ˦¼ðáç malignant PEComa, »ÒµÜ, 54ºÐ½÷À­
     
  • case04: ÉÚºÙ˦À­·ì´ÉÀþ°Ý¼ð Cellular angiofibroma ç´, 35ºÐ½÷À­
     
  • case05: Àá³°À­Rosai-DorfmanÉ¡¡ÆýÁ£, 21ºÐ½÷À­
     
  • case06: Budd-Chiari¾É¸õ·²¡¡´Î¡, 19ºÐÃËÀ­
     
  • case07: ¿À·ÐÀá¿À·Ð¼ð¡¡½Ä³Ö, 3ºÐ½÷»ù
     
  • case08: ž°ÜÀ­¿À·ÐÆâʬÈç¼ðáç¡¡´Î¡, 74ºÐÃËÀ­
     
  • case09: Þù±ÕÀ­´â¡¡Ê¢Ëì, 57ºÐ½÷À­
     
  • case10: ´ÎºÙ˦Á£¼ð-HNF(hepatic nuclear factor)1¦ÁÉԳ貽¤òȼ¤¦. ´Î¡, 39ºÐ½÷À­

źÉÕ¥Õ¥¡¥¤¥ë: fileTCR-APC interaction.txt 713·ï [¾ÜºÙ]

¥È¥Ã¥×   ÊÔ½¸ Åà·ë º¹Ê¬ ¥Ð¥Ã¥¯¥¢¥Ã¥× źÉÕ Ê£À½ ̾Á°Êѹ¹ ¥ê¥í¡¼¥É   ¿·µ¬ °ìÍ÷ ñ¸ì¸¡º÷ ºÇ½ª¹¹¿·   ¥Ø¥ë¥×   ºÇ½ª¹¹¿·¤ÎRSS
Last-modified: 2021-01-04 (·î) 08:05:50 (100d)